Dosage Chart

KLOW Dosage Chart

KLOW dosage chart — how to reconstitute the 80 mg blend, tiered subcutaneous protocols with per-component unit math, and the TB-500 accumulation caveat.

Last updated · 2026-08-04
Source this stack
GHK-Cu12 vetted vendors

Save 15% with code VIALBASE

See all 12 sources →
KPV11 vetted vendors

Save 15% with code VIALBASE

See all 11 sources →
BPC-15712 vetted vendors

Save 15% with code VIALBASE

See all 12 sources →
TB-50012 vetted vendors

Save 15% with code VIALBASE

See all 12 sources →

VialBase may earn a commission on partner links — never at extra cost to you. Disclosure.

Reconstitution

80 mg KLOW vial (GHK-Cu 50 mg / KPV 10 mg / BPC-157 10 mg / TB-500 10 mg) in 2 mL bacteriostatic water

Reconstituted at 80 mg / 2 mL, the blend is 40 mg/mL. On a U-100 syringe, 10 units = 0.1 mL = 4 mg of blend; GHK-Cu sits at 25 mg/mL, the other three at 5 mg/mL each.

The KLOW dosage chart covers how to reconstitute the 80 mg blend and the tiered subcutaneous protocols below, with the per-component milligram math for each draw. KLOW is a fixed-ratio blend — you titrate the vial, not the individual peptides — so the tiers move the whole blend up or down together.

Dosage protocols

Starter (titration)

10 units · 0.1 mL · 4 mg blend
Once daily, 3–5 days
  • GHK-Cu 2.5 mg
  • KPV 500 mcg
  • BPC-157 500 mcg
  • TB-500 500 mcg
Cycle: Assess tolerance before increasing

Start low to gauge injection-site and systemic tolerance before moving to the standard draw. 10 units delivers BPC-157, KPV and TB-500 at 500 mcg each — in range for their typical standalone doses.

TB-500-moderated cadence

20 units · 0.2 mL · 8 mg blend
Every other day, or 4–5 days/week
  • GHK-Cu 5 mg / dose
  • KPV 1 mg / dose
  • BPC-157 1 mg / dose
  • TB-500 1 mg / dose
Cycle: 4–6 weeks, then washout

Because TB-500 has a ~14-day half-life, daily blend dosing accumulates more TB-500 than a typical 2–5 mg/week standalone schedule. Dosing every other day moderates cumulative TB-500 while keeping the shorter-half-life components (GHK-Cu, KPV, BPC-157) effective. If you need independent per-peptide control, dose the components separately instead of the blend.

Your vial, your numbers

Different vial size or water volume? Recalculate your exact draw.

KLOW blend

Syringe Size

Draw to mark

20u(0.200 mL)

Concentration

40000 mcg / mL

For research purposes only. Verify all calculations independently before use.

020406080100
20u
100u syringe

From vial to injection

  1. Sanitize Wipe the vial stopper and the bacteriostatic-water vial stopper with fresh alcohol swabs and let them dry.
  2. Draw the diluent Draw 2 mL of bacteriostatic water into a reconstitution syringe.
  3. Add water slowly Insert the needle at an angle and let the water run down the inside wall of the peptide vial — do not spray it directly onto the powder.
  4. Swirl, don't shake Gently swirl or roll the vial until fully dissolved. Never shake — agitation can degrade the peptides.
  5. Draw your dose With a U-100 insulin syringe, draw to the unit mark for your tier (10 units = 0.1 mL, 20 units = 0.2 mL).
  6. Inject subcutaneously Inject into subcutaneous fat (abdomen or flank), rotating sites. Store the reconstituted vial at 2–8 °C and use within 28 days.

Feeling something? Check here

Normal — expected
  • Mild, transient injection-site redness, itch or a small welt that fades within an hour
  • A brief flushing or warmth after the copper-peptide component
  • Temporary fatigue in the first few days as you titrate
Back off & reassess
  • Persistent headache, lightheadedness or nausea that doesn't settle — back off to the starter draw and reassess
  • Injection-site lumps, swelling or bruising that linger more than a day — rotate sites and check technique
  • Loose stools or GI upset — space dosing and confirm your reconstitution is sterile
Stop & seek care
  • Chest tightness, difficulty breathing, or facial/throat swelling — stop immediately and seek emergency care (possible allergic reaction)
  • Signs of infection at an injection site — spreading redness, heat, pus, fever
  • Any new or growing lump elsewhere — peptides that drive tissue growth are contraindicated with active or suspected cancer

General subcutaneous-peptide safety guidance; TB-500 tolerability anchored to a phase-1 thymosin β4 trial (54 healthy volunteers, 0.05–25 mcg/kg IV, mild-to-moderate adverse events, no dose-limiting toxicity).

This self-check is educational, not a diagnosis. When in doubt, stop dosing and consult a qualified healthcare provider.

Frequently Asked Questions

How do you reconstitute and dose the KLOW blend?
Reconstitute the 80 mg vial with 2 mL bacteriostatic water (40 mg/mL blend). Inject subcutaneously once daily, starting near 10 units (0.1 mL) to assess tolerance and working up to 10–20 units. Because TB-500 has a roughly 14-day half-life, some people dose every other day to avoid over-accumulating it. Store reconstituted blend at 2–8 °C and use within 28 days.
How much of each peptide is in a 20-unit dose?
At 80 mg / 2 mL, a 20-unit (0.2 mL) draw delivers GHK-Cu 5 mg, KPV 1 mg, BPC-157 1 mg, and TB-500 1 mg. A 10-unit draw delivers half of each: GHK-Cu 2.5 mg and 500 mcg of each of the other three.
Why dose KLOW every other day instead of daily?
TB-500's ~14-day half-life means daily blend dosing accumulates more TB-500 than a standalone 2–5 mg/week schedule. An every-other-day or 4–5-day/week cadence moderates cumulative TB-500 while keeping the shorter-half-life components effective. If you need independent control of one peptide, dose the components separately rather than the fixed-ratio blend.
Is KLOW FDA-approved?
No. All four peptides are research-use-only in the US and none is on the 503A bulks list or in any FDA interim category that would permit compounding. Community dosing guides are a starting point, not medical advice. Avoid with active cancer or during pregnancy, and consult a qualified provider.

Sources

Full KLOW stack profile →